Although patients who experienced recent MI may be at greater risk for developing CV death and HF events, our analysis demonstrated that SGLT2 inhibitors were also effective in lowering HF hospitalization rates in patients with previous MI (p = 0.56). The gene discussed is SLC5A2; the disease is hydrops fetalis.